Effect of CACICOL20 on Corneal Epithelial Healing After Cross-linking in Patients With Keratoconus
Primary Purpose
Keratoconus
Status
Completed
Phase
Phase 4
Locations
Austria
Study Type
Interventional
Intervention
RGTA OTR 4120 (CACICOL20)
Genteal HA eye drops
Sponsored by
About this trial
This is an interventional treatment trial for Keratoconus focused on measuring Cross-linking, RGTA OTR4120 (CACICOL20)
Eligibility Criteria
Inclusion Criteria:
- Men and women aged over 18 years
- Presence of keratoconus
- Scheduled for corneal cross linking
- No ophthalmic surgery in the 3 months preceding the study
Exclusion Criteria:
- Participation in a clinical trial in the previous 3 weeks
- Topical use of aminoglycosid antibiotics
- Use of therapeutic or refractive contact lenses after surgery
- Known hypersensitivity to any component of the study medication or heparinoids or heparin
- Active ocular infection
- Presence of any abnormalities preventing reliable measurements as judged by the investigator
- Pregnancy, planned pregnancy or lactating
Sites / Locations
- Department of Clinical Pharmacology, Medical University of Vienna
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
RGTA OTR 4120 (CACICOL20)
Genteal HA
Arm Description
Outcomes
Primary Outcome Measures
Time to closure of the epithelial wound
Secondary Outcome Measures
Full Information
NCT ID
NCT02119039
First Posted
March 21, 2014
Last Updated
December 21, 2015
Sponsor
Medical University of Vienna
1. Study Identification
Unique Protocol Identification Number
NCT02119039
Brief Title
Effect of CACICOL20 on Corneal Epithelial Healing After Cross-linking in Patients With Keratoconus
Official Title
Effect of CACICOL20 on Corneal Epithelial Healing After Cross-linking in Patients With Keratoconus
Study Type
Interventional
2. Study Status
Record Verification Date
December 2015
Overall Recruitment Status
Completed
Study Start Date
July 2014 (undefined)
Primary Completion Date
October 2015 (Actual)
Study Completion Date
December 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Medical University of Vienna
4. Oversight
5. Study Description
Brief Summary
CACICOL20 is an ophthalmic solution based on the technology of RGTAs (ReGeneraTingAgents). It consists of large biopolymers, imitating the structure of heparansulphate. The protecting effect on different biological tissues and enhancement of wound healing has been described in several studies.
Keratoconus is a relatively common disease, with incidences ranging from 1.3 to 25 per 100,000 per year across different populations. Corneal collagen cross-linking represents a treatment option for these patients, aiming to prevent progression of the disease via stabilization of corneal microstructure. Corneal epithelial removal prior to the ultraviolet A/riboflavin cross-linking procedure significantly improves the outcome of the intervention, due to ameliorated distribution of riboflavin.
The aim of the present study is to investigate the effect of CACICOL20 on corneal epithelial wound closure after collagen cross-linking in patients with keratoconus. Results may lead to an improved management and pain reduction of patients with corneal epithelial defects.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Keratoconus
Keywords
Cross-linking, RGTA OTR4120 (CACICOL20)
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
40 (Actual)
8. Arms, Groups, and Interventions
Arm Title
RGTA OTR 4120 (CACICOL20)
Arm Type
Experimental
Arm Title
Genteal HA
Arm Type
Active Comparator
Intervention Type
Device
Intervention Name(s)
RGTA OTR 4120 (CACICOL20)
Intervention Type
Device
Intervention Name(s)
Genteal HA eye drops
Primary Outcome Measure Information:
Title
Time to closure of the epithelial wound
Time Frame
5 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Men and women aged over 18 years
Presence of keratoconus
Scheduled for corneal cross linking
No ophthalmic surgery in the 3 months preceding the study
Exclusion Criteria:
Participation in a clinical trial in the previous 3 weeks
Topical use of aminoglycosid antibiotics
Use of therapeutic or refractive contact lenses after surgery
Known hypersensitivity to any component of the study medication or heparinoids or heparin
Active ocular infection
Presence of any abnormalities preventing reliable measurements as judged by the investigator
Pregnancy, planned pregnancy or lactating
Facility Information:
Facility Name
Department of Clinical Pharmacology, Medical University of Vienna
City
Vienna
ZIP/Postal Code
1090
Country
Austria
12. IPD Sharing Statement
Citations:
PubMed Identifier
27584715
Citation
Bata AM, Witkowska KJ, Wozniak PA, Fondi K, Schmidinger G, Pircher N, Szegedi S, Aranha Dos Santos V, Pantalon A, Werkmeister RM, Garhofer G, Schmetterer L, Schmidl D. Effect of a Matrix Therapy Agent on Corneal Epithelial Healing After Standard Collagen Cross-linking in Patients With Keratoconus: A Randomized Clinical Trial. JAMA Ophthalmol. 2016 Oct 1;134(10):1169-1176. doi: 10.1001/jamaophthalmol.2016.3019.
Results Reference
derived
Learn more about this trial
Effect of CACICOL20 on Corneal Epithelial Healing After Cross-linking in Patients With Keratoconus
We'll reach out to this number within 24 hrs